Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1<i>H</i>-pyrazol-1-yl)methyl)phosphonate (BMS-820132)-Reference-Cited by-同舟云学术

Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1H-pyrazol-1-yl)methyl)phosphonate (BMS-820132)

Published:2022-02-18 Issue:5 Volume:65 Page:4291-4317
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Shi Yan¹^ORCID,Wang Ying¹,Meng Wei¹^ORCID,Brigance Robert P.¹,Ryono Denis E.¹,Bolton Scott¹,Zhang Hao¹,Chen Sean¹,Smirk Rebecca¹,Tao Shiwei¹,Tino Joseph A.²,Williams Kristin N.¹,Sulsky Richard¹,Nielsen Laura¹,Ellsworth Bruce¹^ORCID,Wong Michael K. Y.³,Sun Jung-Hui³,Leith Leslie W.³,Sun Dawn³,Wu Dauh-Rurng³,Gupta Anuradha⁴,Rampulla Richard³,Mathur Arvind³,Chen Bang-Chi³,Wang Aiying⁵,Fuentes-Catanio Helen G.⁵,Kunselman Lori⁵,Cap Michael⁵,Zalaznick Jacob⁵,Ma Xiaohui⁵,Liu Heng⁵,Taylor Joseph R.⁵,Zebo Rachel⁵,Jones Beverly⁵,Kalinowski Stephen⁵,Swartz Joann⁵,Staal Ada⁵,O’Malley Kevin⁶,Kopcho Lisa⁶,Muckelbauer Jodi K.⁷,Krystek Stanley R.⁷,Spronk Steven A.⁷^ORCID,Marcinkeviciene Jovita⁶,Everlof Gerry⁸,Chen Xue-Qing⁸,Xu Carrie⁸,Li Yi-Xin⁸,Langish Robert A.⁸,Yang Yanou⁸,Wang Qi⁸,Behnia Kamelia⁸,Fura Aberra⁸,Janovitz Evan B.⁹,Pannacciulli Nicola¹⁰,Griffen Steven¹⁰,Zinker Bradley A.⁵,Krupinski John⁵,Kirby Mark⁵,Whaley Jean⁵,Zahler Robert¹,Barrish Joel C.¹,Robl Jeffrey A.¹,Cheng Peter T. W.¹^ORCID

Affiliation:

1. Fibrosis Chemistry, Small Molecule Drug Discovery, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States

2. Cancer Resistance and Neuroscience Chemistry, Small Molecule Drug Discovery, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States

3. Department of Discovery Synthesis, Small Molecule Drug Discovery, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States

4. Department of Discovery Synthesis, Small Molecule Drug Discovery, Research & Early Development, Biocon-Bristol Myers Squibb Research & Development Center, Bangalore 560099, India

5. Cardiovascular & Fibrosis Discovery Biology, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States

6. Lead Evaluation, Small Molecule Drug Discovery, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States

7. Molecular Structure & Design, Small Molecule Drug Discovery, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States

8. Pharmaceutics, Preclinical Candidate Optimization, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States

9. Drug Development and Preclinical Studies, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States

10. Clinical Pharmacology, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States

Funder

Bristol-Myers Squibb

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c02110

Reference38 articles.

1. Diabetes in numbers

2. A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data

3. New Drugs for Type 2 Diabetes Mellitus

4. Glucokinase activators as potential antidiabetic agents possessing superior glucose lowering efficacies

5. Assessing the potential of glucokinase activators in diabetes therapy

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Six-membered ring systems: diazines and benzo derivatives;Progress in Heterocyclic Chemistry;2023